Carisoprodol
Carisoprodol, Soma (carisoprodol) is a small molecule pharmaceutical. Carisoprodol was first approved as Soma on 1982-01-01. It is used to treat muscle cramp, muscle rigidity, muscle spasticity, myositis, and pain amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Carisoprodol, Soma (discontinued: Carisoprodol, Rela, Soma)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Carisoprodol
Aspirin
+
Carisoprodol
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aquabain antibacterial fresh and relax | C200263 | 2024-12-02 |
| carisoprodol | ANDA | 2025-07-30 |
| carisoprodol and aspirin | ANDA | 2010-12-10 |
| carisoprodol tablets, usp, 350 mg | ANDA | 2025-09-16 |
| cbd clinic relax massage | C200263 | 2025-01-28 |
| chakra aroma relaxing color | OTC monograph not final | 2019-02-19 |
| coupling chamomile relax premium massagelotion | unapproved drug other | 2022-01-13 |
| coupling lavender relax premium massagelotion | unapproved drug other | 2022-01-13 |
| curestem cell healer c10 program | unapproved drug other | 2020-06-08 |
| curestem cell healer c5 program | unapproved drug other | 2020-06-05 |
Show 54 more
Indications
FDA
EMA
Show 3 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M03: Muscle relaxants
— M03B: Muscle relaxants, centrally acting agents
— M03BA: Carbamic acid esters, centrally acting muscle relaxants
— M03BA02: Carisoprodol
— M03BA52: Carisoprodol, combinations excl. psycholeptics
— M03BA72: Carisoprodol, combinations with psycholeptics
HCPCS
No data
Clinical
Clinical Trials
41 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Low back pain | D017116 | — | M54.5 | — | — | 2 | — | — | 2 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Carisoprodol |
| INN | carisoprodol |
| Description | Carisoprodol is a carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. It has a role as a muscle relaxant. |
| Classification | Small molecule |
| Drug class | Carbamate |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCC(C)(COC(N)=O)COC(=O)NC(C)C |
Identifiers
| PDB | — |
| CAS-ID | 78-44-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1233 |
| ChEBI ID | 3419 |
| PubChem CID | 2576 |
| DrugBank | DB00395 |
| UNII ID | 21925K482H (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Opdualag – Bristol Myers Squibb
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Somavert – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Genotropin – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Carisoprodol
+
Aspirin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Carisoprodol
+
Aspirin
+
Codeine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Carisoprodol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 33,042 documents
View more details
Safety
Black-box Warning
Black-box warning for: Relafen ds
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
100,606 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use